» Articles » PMID: 28861211

Adverse Effects of Proton-pump Inhibitor Use in Older Adults: a Review of the Evidence

Overview
Publisher Sage Publications
Date 2017 Sep 2
PMID 28861211
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Proton-pump inhibitors (PPIs) are a widely prescribed class of medications used to treat acid-related disorders and use has significantly increased over the last few decades. PPIs are often inappropriately prescribed and since they have been on the market, a number of post-marketing studies have been published demonstrating associations between longer duration of PPI therapy and a number of adverse effects that are a concern in older adults. The objective of this review is to discuss the existing literature of potential adverse effects with long-term PPI use in older adults and to summarize the implications in clinical practice. A search was conducted to identify studies evaluating the potential long-term adverse effects of PPI therapy in older adults, and publications were selected based on relevant criteria. PPIs have been associated with an increased risk of a number of adverse effects including osteoporotic-related fractures, infection, community-acquired pneumonia, vitamin B12 deficiency, kidney disease, and dementia, demonstrated by a number of case-control, cohort studies, and meta-analyses. Older adults should be periodically evaluated for the need for continued use of PPI therapy given the number of potential adverse effects associated with long-term use.

Citing Articles

Initial Diagnostic Strategies for Helicobacter Pylori in Patients With Bleeding Peptic Ulcers Undergoing Endoscopy: A Cost-Effectiveness Analysis.

Artin M, Soddano J, Rustgi S, Aziz Z, Lim F, Yang J Gastro Hep Adv. 2025; 4(4):100602.

PMID: 39996244 PMC: 11849076. DOI: 10.1016/j.gastha.2024.100602.


The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): study protocol for a randomised placebo-controlled multicentre clinical trial.

Jones M, Cahn A, Chaudhuri N, Clark A, Forrest I, Hammond M BMJ Open. 2025; 15(2):e088604.

PMID: 39909521 PMC: 11800218. DOI: 10.1136/bmjopen-2024-088604.


[Stroke in octogenarians].

Reith W, Bachhuber A Radiologie (Heidelb). 2025; 65(2):85-93.

PMID: 39847095 DOI: 10.1007/s00117-024-01405-x.


Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review.

Ngcobo N Clin Pharmacokinet. 2025; .

PMID: 39798015 DOI: 10.1007/s40262-024-01466-0.


Patterns of outpatient proton‒pump inhibitors use among older adults in a duplicative health system: comparing public and private prescribing.

Romano S, Rodrigues A, Torre C, Perelman J BMC Health Serv Res. 2025; 25(1):30.

PMID: 39762802 PMC: 11706009. DOI: 10.1186/s12913-024-12033-5.


References
1.
Cunningham R, Dale B, Undy B, Gaunt N . Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003; 54(3):243-5. DOI: 10.1016/s0195-6701(03)00088-4. View

2.
Berney-Meyer L, Hung N, Slatter T, Schollum J, Kitching A, Walker R . Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury?. Nephrology (Carlton). 2014; 19(6):359-65. DOI: 10.1111/nep.12226. View

3.
Stupka J, Mortensen E, Anzueto A, Restrepo M . Community-acquired pneumonia in elderly patients. Aging health. 2011; 5(6):763-774. PMC: 2917114. DOI: 10.2217/ahe.09.74. View

4.
Hermos J, Young M, Fonda J, Gagnon D, Fiore L, Lawler E . Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis. 2011; 54(1):33-42. DOI: 10.1093/cid/cir767. View

5.
Maggio M, Lauretani F, Ceda G, De Vita F, Bondi G, Corsonello A . Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013; 57(2):437-42. PMC: 6125777. DOI: 10.1016/j.bone.2013.09.014. View